Helex is a New York–based therapeutics company creating a new class of targeted medicines for genetic kidney disorders using programmable non-viral lipid nanoparticles (LNPs). Its lead program addresses Autosomal Dominant Polycystic Kidney Disease (ADPKD), an inherited condition driven by PKD1 and PKD2 mutations that affects over 12 million people globally. The firm integrates an AI-powered drug-design platform with its proprietary LNP delivery technology to localize therapeutic cargo directly to kidney cells. Funds from its newest financing are earmarked for IND-enabling studies of the ADPKD candidate and for broadening the development pipeline. Helex operates from New York and ASPIRE BioNEST in Hyderabad and receives support from Bayer Co.Lab Cambridge. Including the latest raise, the company has secured more than $6 million in total funding, reflecting early investor confidence in its kidney-targeted approach.

Total raised

$4M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2025